To date no randomized controlled trials have been completed that demonstrated whether TACE(Transarterial chemoembolization) is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in conversion resection rates and survival compared with chemotherapy (target therapy) alone for patients who failed with first-line chemotherapy.The primary objective of this trial is to determine conversion resection rates and survival for patients with colorectal cancer liver metastasis are treated with TACE plus chemotherapy ± target therapy, compared to chemotherapy ± target therapy in the 2nd, and 3rd line.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
168
TACE
chemotherapy±target therapy
Department of General Surgery, Zhongshan Hospital, Fudan University
Shanghai, China
Progression free survival
Time frame: 6 months
overall survival
Time frame: 6 months
conversion resection rates
Time frame: 2-4months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.